Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy
| Autor: | L. Franchino, Giuseppe Romanelli, A. Pozzi, Paolo Donati, Paola Prometti, Cravarezza P, Vittorio Grassi, Roberto Zulli, G. Ravizzola |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Male
medicine.medical_specialty Imipenem community-acquired pneumonia Cilastatin Imipenem Drug Combination Meropenem elderly Drug Costs Community-acquired pneumonia Carbapenems Clarithromycin Internal medicine Pneumonia Bacterial polycyclic compounds medicine Humans Pharmacology (medical) Prospective Studies Aged Antibacterial agent Aged 80 and over Pharmacology Cilastatin business.industry Ceftriaxone biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Anti-Bacterial Agents Surgery Community-Acquired Infections Hospitalization Drug Combinations Treatment Outcome Infectious Diseases Oncology Amikacin Costs and Cost Analysis Drug Therapy Combination Female Thienamycins business medicine.drug |
| Popis: | In this open, prospective, study were enrolled 204 hospitalized elderly patients with severe (88 males, 116 females, age range 70-94). Patients were randomized to receive one of the following antibiotic treatment regimens: meropenem 500 mg i.v. t.i.d. (52); imipenem/cilastatin 500 mg i.v. t.i.d. (51), clarithromycin 500 mg + ceftriaxone 1 g i.v. b.i.d. (52), clarithromycin 500 mg + amikacin 250 mg i.v. b.i.d. (49). In 99 cases causative germs were isolated (24 meropenem, 26 imipenem, 23 clarithromycin + ceftriaxone, 26 ceftriaxone + amikacin). A satisfactory clinical, bacteriological response was achieved respectively in 86.5% 77% in meropenem; 86.3% 71% in imipenem/cilastatin; 69% 61% in ceftriaxone + clarithromycin and in 85.7% 77% in clarithromycin + amikacin. The mean total cost for each patient was $1,560; $1,620; $1,760 and $1,792 in meropenem, imipenem/cilastatin, clarithromycin + ceftriaxone and clarithromycin + amikacin respectively. This study shows that treatment with either meropenem or imipenem is as efficacious as conventional therapy in the treatment of community acquired pneumonia (CAP), and that meropenem is the most cost-effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|